|
|
Simultaneous determination of puerarin, daidzein, aurantio-obtusin and chrysophanol in Liuwei Gelan Jiangzhi Tablets by HPLC |
XIAO Ming1 ZHOU Yaqi2 LI Fangchan3 JIANG Lin3 WEI Bowei2 |
1.Health Food Branch of Guangxi Zhuang Yao Pharmaceutical Engineering Technology Research Center, Guangxi Zhuang Autonomous Region, Nanning 530023, China;
2.Graduate School of Guangxi University of Chinese Medicine, Guangxi Zhuang Autonomous Region, Nanning 530001, China;
3.School of Pharmacy, Guangxi University of Chinese Medicine, Guangxi Zhuang Autonomous Region, Nanning 530001, China |
|
|
Abstract Objective To establish a high performance liquid chromatography method for the simultaneous determination of puerarin, daidzein, aurantio-obtusin and chrysophanol in Liuwei Gelan Jiangzhi Tablets. Methods High performance liquid chromatography method was used. Phenomenex Gemini C18 (250 nm × 4.6 mm, 5 um) was used as the chromatographic column. The mobile phase was acetonitrile-0.1% phosphoric acid aqueous solution. The gradient elution method was used. The detection wavelength was 285 nm, the column temperature was 30℃, and the flow rate was 1.0 mL/min. Results The injection quantities of puerarin, daidzein, aurantio-obtusin and chrysophanol showed good linear relationship with peak area in the range of 0.014 58-0.065 62 mg/mL, 0.1074-0.2417 mg/mL, 0.014 58-0.065 62 mg/mL, 0.012 01-0.054 04 mg/mL (r = 0.995 94, 0.999 95, 0.999 97, 0.991 57), respectively, and the average recovery rates were 99.0%, 102.9%, 104.1%, 104.1%, and RSD were 0.390%, 0.910%, 0.050%, 0.057% (n = 6), respectively. Conclusion The method is simple, accurate, stable and reproducible. It can be used for the quality control of Liuwei Gelan Jiangzhi Tablets.
|
|
|
|
|
[1] 农毅清.药食两用中药降血脂活性成分的研究概况[J].广西中医药,2016,39(1):4-7.
[2] 食品市场资讯.美、日心血管类保健食品现状与发展趋势[J].中国食品学报,2007,7(4):119.
[3] 杨勇,阚健全,赵国华,等.血管内皮功能与调节心血管功能保健食品的功能评价[J].食品科学,2004,25(8):173-176.
[4] 钱勇.保健食品领跑降脂降糖产品市场[N].医药导报,2006,3(C19):1-2.
[5] 农毅清,蒋林,罗宇东,等.六味葛蓝降脂片质量标准研究[J].食品与药品,2016,18(3):170-174.
[6] 何菊英,刘松青,彭永富,等.决明子降血脂作用机制研究[J].中国药房,2003,14(4):10-12.
[7] 赵淑芹.葛根的药理作用与临床应用[J].中国医药科学,2013,3(2):40-43.
[8] 王青,张伟东,宋小妹,等.HPLC法同时测定不同产地决明子中12种蒽醌类成分的含量[J].解放军药学学报,2012,28(6):502-505.
[9] 冯艳平.决明子降血脂有效成分探讨[J].中国医药指南,2013,11(5):258-259.
[10] 黄小平,钟国跃,张雪梅,等.HPLC法测定决明子中大黄酚和橙黄决明素[J].中国中药杂志,2010,35(16):2065-2067.
[11] 崔苏镇,彭学莲.葛根的药理作用研究概况[J].时珍国医国药,1998,9(3):90-91.
[12] Song W,Li Y,Qiao X,et al. Chemistry of the Chinese herbal medicine Puerariae Radix(Ge-Gen):A review [J]. Chin Pharm Sci,2014,23(6):347-360.
[13] 姚丹,丁选胜.葛根素药理作用机制探讨及临床应用[J].中国临床药理学与治疗学,2008,13(4):468-474.
[14] 尹丽红,李艳枫,孟繁琳,等.葛根的化学成分、药理作用和临床应用[J].黑龙江医药,2010,23(3):371-373.
[15] 郑高利.大豆异黄酮的药理作用Ⅰ[J].中国现代应用药学,1998,15(1):4-5.
[16] 何菊英,刘松青,彭永富,等.决明子降血脂作用机制研究[J].中国药房,2003,14(4):10-12.
[17] 李明元,罗孟军,叶娉,等.橙黄决明素的降血脂作用研究[J].中药药理与临床,2008,24(6):36-37.
[18] 沈奇桂,朱寿民.决明子对实验性高胆固醇血症和动脉粥样硬化的抑制作用及其机理探讨[J].浙江医科大学学报,1993,22(6):246-249.
[19] 石勇,吴正奇.葛根和葛根保健品的国内外研究进展[J].湖北工学院学报,2000,15(1):52-55.
[20] 李和伟,赵彤,董玲,等.口服葛根的肠代谢特征分析[J].国际中医中药杂志,2014,36(2):131-134.
[21] Choo MK,Park EK,Yoon HK,et al. Antithrombotic and antiallergic activities of daidzein,a metabolite of puerarin and daidzin produced by human intestinal microflora [J]. Biol Pharm Bull,2002,25(10):1328. |
|
|
|